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SI Methods 
Cell culture  
U-87 MG cells were obtained from ATCC (Manassas, VA) and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Thermo Fisher) supplemented with 10% fetal bovine serum (Thermo 
Fisher) in a humidified 5% CO2 atmosphere at 37°C.  
 
Tumor spheroid sample preparation 
Tumor spheroids were formed using Mcf10a-HRas cell lines (kindly provided by Prof. Prives, 
Columbia University, NY) cultured in 1x DMEM/F-12 medium supplemented with 5% (v/v) horse 
serum, 1% (v/v) 100x penicillin/ streptomycin/amphotericin B solution (MP Biomedicals, Solon, 
OH), 0.5 μg/mL hydrocortisone (Sigma-Aldrich), 10 μg/mL insulin (Sigma-Aldrich), 0.1 μg/mL 
cholera toxin (Sigma-Aldrich), and 20 ng/mL epidermal growth factor (Sigma-Aldrich). 
Tumor spheroids were formed with the centrifugation method as previously described (1). In brief, 
cells were detached through Accutase treatment, brought into suspension in ice-cold culture 
medium containing 0.2575 mg/ml basement membrane extract (BME) and centrifuged at 4°C for 
10 min at 1000-1200 g in a Sorvall desktop centrifuge in ultra-low adhesion U-bottom 96-well 
culture plates (Thermo Fisher Scientific Nunclon Sphera microplates, Waltham, MA). Culture 
plates were then transferred to an incubator for 24 h at 37°C with 5% carbon dioxide for tumor 
spheroid compaction. Tumor spheroids were treated with Cell Recovery Solution (Corning, 
Corning, NY) for 45-65 min at 4°C prior to embedding in 3D matrices to remove the layer of BME 
of variable thickness, density, and continuity which would obstruct uniform invasion.  
Single tumor spheroids pre-treated with Cell Recovery Solution were placed into composite 
collagen I/BME biopolymer matrices containing the appropriate concentration of the deuterated 
lipid probe, each of which could then be gelled around the tumor spheroid. For composite collagen 
I/BME gels, first 10x DMEM, HEPES buffer, deuterated lipid probe and sodium bicarbonate were 
mixed. Then, the required amount of BME stock solution (8.9-10 mg/ml) was added to reach the 
final concentration of 3 mg/ml. The BME replaced a proportion of the ddH2O that would be added 
in the equivalent pure collagen I gel. Next the collagen stock solution was added to achieve a 
concentration of 1 mg/ml, and the solution was brought to pH 7.4 by adding NaOH. 
Subsequently, 80 µl of the neutralized collagen/BME solution was transferred to a chamber 
consisting of an adhesive silicone isolator (Press-to-Seal Invitrogen, 9 mm diameter, 1 mm depth) 
attached to a coverslip-bottom cell culture dish and a single MTS was added to the biopolymer 
matrix. The gel chamber was then transferred to the 37°C incubator. After completion of gelation 
(t = 1 h) the gels were overlaid with 30 μL culture medium containing 20 µM deuterated palmitic 
acid and surrounded by 500 μL culture medium to prevent drying during extended monitoring. For 
deuterated palmitic acid solution, palmitic acid-d31 (98% D, 366897, Sigma-Aldrich) were reacted 
with sodium hydroxide (Sigma-Aldrich) above melting point to form 20 mM solution, and then 
coupled to fatty-acid-free BSA (A7030, Sigma-Aldrich) in about 2:1 molar ratio to make 2 mM 
stock solution in culture medium. The stock solution was then added to culture medium to a final 
concentration of 20 µM. 
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Mouse brain and glioblastoma xenograft sample preparation 
The animal experimental protocol (AC-AAAQ0496) was approved by the Institutional Animal 
Care and Use Committee at Columbia University. 
Adult female wild type mice (C57BL/6, 12 weeks old, Jackson Lab) were fully anesthetized using 
isoflurane, then sacrificed with cervical displacement and immediately perfused with 4% PFA in 
PBS transcardially. The whole brain was extracted and fixed in 4% PFA in PBS at 4 °C for 24 h. 
After post-fixation, the brain was sectioned into 1 mm thick coronal slices using a vibratome 
(VT1000S, Leica).  
To obtain glioblastoma xenograft in brain, we performed intracranial implantation of U-87 MG 
human glioma cells. Briefly, a nude mouse (J:NU, Jackson Lab) was anesthetized and positioned 
in a stereotaxic instrument (David Kopf Instruments), and then a small section (2 mm in diameter) 
of the skull was ground with a dental drill until it became soft and translucent. Subsequently, we 
injected 1.5×105 U87-MG cells (in 3 μL) into the frontal region of the cerebral cortex over the 
course of 5 minutes using a glass capillary. After the implantation, mouse head skin was then 
closed with SILK sutures (Harvard Apparatus). 2~3 weeks later, mice bearing glioblastoma were 
anesthetized, sacrificed, fixed, and sliced for clearing and SRS imaging.  
For subcutaneous glioblastoma xenograft, we injected subcutaneously 1×107 U87-MG cells into 
the lower flank of nude mice. After ~10 days, tumor bearing mice were anesthetized, sacrificed, 
fixed, and sliced for clearing and SRS imaging. 
 
Deuterium oxide (D2O) labeling of glioblastoma xenograft 
D2O labeling of glioblastoma xenograft was performed as previously described (2). Briefly, after 
intracranial implantation of U87-MG cells in nude mice, tumors were allowed to grow for 10 days. 
Tumor-bearing mice were then given 25% D2O as drinking water for 15 days before being 
sacrificed and fixed. After post-fixation, tumor xenograft samples were sectioned into 1 mm thick 
coronal slices for clearing and SRS imaging and sectioned into 40 μm coronal slices for 
immunolabeling and correlative immunofluorescence and SRS imaging. 
 
Tissue clearing 
For tumor spheroid samples, the clearing solution (8 M urea) was prepared by adding 16 mL 
deionized water to the product vial (U4883, Sigma-Aldrich). Tumor spheroid samples were 
immersed in the clearing solution for more than four days at room temperature and were then 
mounted in the clearing solution for stimulated Raman scattering microscopy. 
For mouse brain and glioblastoma xenograft samples, the clearing solution (8 M urea and 0.2% 
Triton X-100) was prepared by diluting Triton X-100 (H5142, Promega) in 8 M urea (8 M after 
adding 16 mL deionized water, U4883, Sigma-Aldrich) to a final concentration of 0.2%. Samples 
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were immersed in the clearing solution for more than four days at room temperature and were then 
mounted in the clearing solution for Raman spectroscopy or SRS microscopy. 
For samples that underwent 15% treatment (Fig. S4), brain slices were immersed in the solution 
of 8 M urea and 15% Triton X-100 for 4 days and then in the clearing solution of 8 M urea and 
0.2% Triton X-100 for four days at room temperature. After that, the samples were mounted in the 
clearing solution (8 M urea and 0.2% Triton X-100) for Raman spectroscopy or SRS microscopy. 
For samples that underwent 3DISCO treatment (Fig. S5), brain slices were processed using 
3DISCO procedures as previously reported (3). After that, the samples were immersed in PBS for 
four days at room temperature and were then mounted in PBS for Raman spectroscopy or SRS 
microscopy. 
 
Immunolabeling of glioblastoma xenograft 
After post-fixation, D2O labeled glioblastoma xenografts was sectioned into 40 μm coronal slices 
using a vibratome (VT1000S, Leica). Tumor slices were washed three times for 5 min each using 
PBS. Samples were then permeabilized with 0.5% Triton X-100 in PBS for 10 min and washed 
twice with 10% goat serum/1% BSA/0.3 M glycine solution. After that samples were incubated 
with a human-specific anti-vimentin antibody (mouse monoclonal [V9] to vimentin, ab8069, 
Abcam) at 1:200 dilution in 3% BSA overnight at 4 °C. Samples were washed twice for 5 min 
each time using PBS and washed once using 10% goat serum. Samples were then blocked with 
10% goat serum for 30 min. After that samples were incubated with goat anti-mouse IgG 
conjugated with Alexa Fluor 647 (A21236, Invitrogen) at 1:500 dilution in 10% goat serum 
overnight at 4 °C. Samples were then washed with PBS before imaging. 
 
Spontaneous Raman spectroscopy 
Spontaneous Raman spectra were acquired using an upright confocal Raman spectrometer 
(Xplora, HORIBA Jobin Yvon). Samples were illuminated by 532 nm (25 mW) laser through a 
50× objective (air, NA 0.75, MPlan N, Olympus). The acquisition time was 10 s with 5× 
accumulation. For the spectra of tissue samples, at least three different regions were randomly 
chosen and their spectra were averaged. 
 
Stimulated Raman scattering (SRS) microscopy 
An integrated laser (picoEMERALD with custom modification, Applied Physics and Electronics, 
Inc.) was used as a light source for both pump and Stokes beams. Briefly, picoEMERALD 
provided an output pulse train at 1064 nm with 6-ps pulse width and 80-MHz repetition rate, which 
served as the Stokes beam. The frequency-doubled beam at 532 nm was used to synchronously 
seed a picosecond optical parametric oscillator (OPO) to produce a mode-locked pulse train (the 
idler beam of the OPO was blocked with an interferometric filter) with 5-6-ps pulse width. The 
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wavelength of the OPO was tunable from 720 nm to 990 nm, which served as the pump beam. The 
intensity of the 1,064 nm Stokes beam was modulated sinusoidally by a built-in electro-optic 
modulator (EOM) at 8 MHz with a modulation depth of more than 95%. The pump beam was 
spatially overlapped with the Stokes beam with a dichroic mirror inside picoEMERALD. The 
temporal overlap between pump and Stokes pulse trains was ensured with a built-in delay stage 
and optimized by the SRS signal of deuterium oxide (99.9 at% D, 151882 ALDRICH). 
Pump and Stokes beams were coupled into an inverted laser-scanning microscope (FV1200MPE, 
Olympus) optimized for near-infrared throughput. A 25× water objective (XLPlan N, 1.05 
numerical aperture (NA), MP, Olympus) with high near-infrared transmission and large field of 
view was used for measurements of all samples. The pump/Stokes beam size was matched to fill 
the back-aperture of the corresponding objectives for imaging. The forward-going pump and 
Stokes beams after passing through the samples were collected in transmission with a high-NA 
condenser lens (oil immersion, 1.4 NA, Olympus), which was aligned following Köhler 
illumination. A telescope was then used to image the scanning mirrors onto a large-area (10 mm 
× 10 mm) Si photodiode (FDS1010, Thorlabs) to descan beam motion during laser scanning. The 
photodiode was reverse-biased by 64 V from a DC power supply to increase the saturation 
threshold and the response bandwidth. A high-optical-density bandpass filter (890/220 CARS, 
Chroma Technology) was used to block the Stokes beam completely and transmit the pump beam 
only. The output current of the photodiode was electronically pre-filtered by an 8-MHz bandpass 
filter (KR 2724, KR electronics) to suppress the 80-MHz laser pulsing and the low-frequency 
contribution due to laser scanning across the scattering sample. It was then fed into a radio-
frequency lock-in amplifier (HF2LI, Zurich instrument), terminated with 50 Ω to demodulate the 
stimulated Raman loss signal experienced by the pump beam. The in-phase X-output of the lock-
in amplifier was fed back into the analogue interface box (FV10-ANALOGUE) of the microscope. 
All laser powers were measured after the objective lens. The pump laser power was 125 mW and 
the Stokes laser power was 175 mW. For the imaging of tumor spheroids, the pixel dwell time was 
8 µs (1.261 s per 320 × 320 frame), the time constant of the lock-in amplifier was 5 µs, and z series 
were captured at 2 µm steps. For the imaging of the mouse brain, tumors, and embryos, the pixel 
dwell time was 4 µs (1.644 s per 512 × 512 frame), the time constant of the lock-in amplifier was 
3 µs, and z series were captured at 4 µm steps. For metabolic volumetric chemical imaging of 
glioblastoma xenograft, the pixel dwell time was 40 µs (11.297 s per 512 × 512 frame), the time 
constant of the lock-in amplifier was 30 µs, and z series were captured at 4 µm steps. The 
wavelength of the Stokes laser was 1064 nm and the wavelengths for the pump laser were 810.5 
nm (2940 cm-1, mainly protein CH3), 816.7 nm (2845 cm-1, mainly lipid CH2), 869.0 nm (2109 
cm-1, C-D for newly synthesized lipids from d-PA), 875.0 nm (2030 cm-1, off-resonance 
background for newly synthesized lipids from d-PA), 863.3 nm (2185 cm-1, C-D for mainly newly 
synthesized proteins from D2O), 867.2 nm (2135 cm-1, C-D for mainly newly synthesized lipids 
from D2O), and 885.0 nm (1901 cm-1, off-resonance background for newly synthesized proteins 
and lipids from D2O). 
 
Multispectral SRS imaging 
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The pump laser power was 125 mW and the Stokes laser power was 175 mW. The pixel dwell 
time was 4 µs (1.644 s per 512 × 512 frame), the time constant of the lock-in amplifier was 3 µs, 
and z series were captured at 8 µm steps. The wavelength of the Stokes laser was 1064 nm. The 
wavelengths for the pump laser were tuned to 800.7 nm (3091 cm-1), 802.5 nm (3063 cm-1), 804.4 
nm (3033 cm-1), 806.2 nm (3005 cm-1), 808.1 nm (2976 cm-1), 809.9 nm (2949 cm-1), 810.5 nm 
(2940 cm-1), 811.7 nm (2921 cm-1), 813.6 nm (2893 cm-1), 815.4 nm (2865 cm-1), 816.7 nm (2845 
cm-1), 817.3 nm (2837 cm-1), and 819.1 nm (2810 cm-1) sequentially for multispectral imaging. A 
whole z-stack image was taken at each wavelength before tuning. 
 
Correlative imaging of immunofluorescence and SRS 
Confocal fluorescence imaging was performed on the inverted laser-scanning microscope 
(FV1200MPE, Olympus) with a 633-nm continuous-wave laser. After fluorescence imaging, we 
switched to SRS imaging mode and collected label-free SRS and DO-SRS signals with the Stokes 
laser (1064 nm, 175 mW) and the pump laser (810.5 nm, 816.7 nm, 863.3 nm, 867.2 nm, and 885 
nm, 125 mW). 
 
Correlative two-photon fluorescence and SRS imaging 
Correlative two-photon fluorescence and SRS imaging was performed with the integrated laser 
(picoEMERALD with custom modification, Applied Physics and Electronics, Inc.) and the 
inverted laser-scanning microscope (FV1200MPE, Olympus). We first tuned the pump laser to 
810.5 nm (125 mW) and used it to collect two-photon excited autofluorescence from the samples. 
We then switched to SRS imaging mode and collected label-free SRS signals with the Stokes laser 
(1064 nm, 175 mW) and the pump laser (810.5 nm and 816.7 nm, 125 mW). 
 
Correlative second-harmonic generation and SRS imaging 
Correlative second-harmonic generation and SRS imaging was performed with the integrated laser 
(picoEMERALD with custom modification, Applied Physics and Electronics, Inc.) and the 
inverted laser-scanning microscope (FV1200MPE, Olympus). We first used the Stokes laser (1064 
nm, 125 mW) to collect second-harmonic generation signals from the samples. We then switched 
to SRS imaging mode and collected label-free SRS signals with the Stokes laser (1064 nm, 175 
mW) and the pump laser (810.5 nm and 816.7 nm, 125 mW). 
 
CH2 and CH3 linear combination algorithm 
In order to obtain total lipid and total protein signals, we adapted a previously reported spectral 
linear combination algorithm (4). Briefly, we acquired the SRS signals from two wavelengths 
bearing features of lipids and proteins and the total amounts of lipids and proteins can be 
determined by a linear combination of the signals at those two wavelengths, with coefficients 
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obtained by pure substances and then fine-tuned and optimized by actual unmixed images. Here, 
signals at 2845 cm-1 and 2940 cm-1 were measured to perform the spectral unmixing: 
Protein: 𝐶𝐻௉ ൌ 𝐼ଶଽସ଴ െ  𝐼ଶ଼ସହ 
Lipid: 𝐶𝐻௅ ൌ  5 ∙  𝐼ଶ଼ସହ െ  0.4 ∙  𝐼ଶଽସ଴ 
where I2845 and I2940 are SRS signal intensities at 2845 and 2940 cm-1, respectively. 
 
CDL and CDP unmixing algorithm 
SRS images at 2185 and 2135 cm-1 were corrected by subtracting off-resonance images at 1901 
cm-1. CDL and CDP signals were then unmixed using the equations (2): 
𝐶𝐷௅ ൌ  1.25 ∙  𝐼ଶଵଷହ െ  0.50 ∙  𝐼ଶଵ଼ହ 
𝐶𝐷௉ ൌ  1.25 ∙  𝐼ଶଵ଼ହ െ  0.64 ∙  𝐼ଶଵଷହ 
where I2135 and I2185 are signal intensities of corrected SRS images at 2135 and 2185 cm-1, 
respectively. 
 
Three dimensional reconstruction 
Raw images were unmixed into two channels—total proteins and total lipids. For tumor spheroids, 
an additional channel of newly synthesized lipids was obtained by subtracting the images acquired 
at 869.0 nm pump laser by that at 875.0 nm pump laser. For metabolic imaging of glioblastoma 
xenograft, raw images were corrected by subtracting off-resonance background and then unmixed 
into two channels of newly synthesized proteins (CDP) and lipids (CDL). A median filter was 
applied to the unmixed images for noise reduction. A Fiji plugin (5) was then applied to the images 
for attenuation correction. The opening radius was set to 0.5 for 512 × 512 frames or 0.2 for 320 
× 320 frames. After correction, the images were volume-rendered in the mode of maximal intensity 
projection using Imaris (Bitplane). 
 
Quantification of imaging depth 
The imaging depths were determined based on z-series images at 2940 cm-1 for label-free images. 
The signal-to-background ratios of the raw images were quantified at different z depths using Fiji 
(6). Specifically, for an image acquired at a specific depth, we drew several lines on the image 
with each line across multiple cells, plotted the intensity profiles for individual lines, calculated 
the signal-to-background ratio for each line (using minimal intensity as the background and 
maximal intensity as the sum of the background and the signal), and averaged the signal-to-
background ratios of these lines as the signal-to-background ratio of the image. The imaging depth 
was determined when the signal-to-background ratio decreased to less than 0.5 at this specific 
depth. 
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Image registration between images before and after clearing 
To confirm that the process of tissue clearing preserved tissue and cellular structures, we imaged 
the same region of the tissue before and after clearing and then registered and compared the two 
images in both total protein and total lipid channels. First, the raw images were unmixed into total 
protein and total lipid channels. Then the unmixed images before and after clearing were registered 
using a Fiji plugin TrakEM2 (7). Four images—total protein before clearing, total protein after 
clearing, total lipid before clearing, and total lipid after clearing—are loaded into four different 
layers in TrakEM2. The image of total proteins after clearing was aligned to that of total proteins 
before clearing using the mode of least squares and similarity transformation. After that, the image 
of total lipids before clearing was aligned to that of total proteins before clearing and the image of 
total lipids after clearing was aligned to that of total proteins after clearing, manually using the 
outer edges of the images. After registration, the protein/lipid ratios were measured and compared 
at the same regions before and after clearing. The fold of expansion after tissue clearing was 
calculated by dividing the length of the edge before clearing by that after clearing. 
 
Ratiometric imaging analysis 
SRS images at 2940 and 2845 cm-1 were acquired by point scanning (pixel size: 1.988 μm) and 
stitched into large-area images using Olympus Fluoview software. Ratiometric imaging analysis 
was performed using ImageJ (8). Raw images were unmixed into protein and lipid channels and 
then corrected with background subtraction. The protein/lipid ratiometric image was calculated as 
the background-corrected protein image divided by the background-corrected lipid image. 
Artifacts outside the brain sample region were removed using a mask image generated from the 
protein image. For each image at a specific depth, mean protein/lipid ratios were measured for 
three regions of interests in the tumor tissue and three regions of interests in the normal tissue. 
Protein/lipid ratios were plotted as a function of imaging depths. CDP/CDL ratiometric images were 
produced similarly. 
 
Volumetric phasor analysis 
The multispectral SRS imaging data were transformed to a phasor plot as described previously (9) 
using custom-written Matlab scripts. Each voxel in the 4D (x-y-z-λ) dataset was transformed to a 
phasor point on a 2D phasor plot using the following equations of Fourier transform: 
𝑢 ൌ  ∑ 𝑆ሺ𝜆௡ሻ cos ሺ2𝜋𝑛 𝑁⁄ ሻ
ே௡ୀଵ
∑ 𝑆ሺ𝜆௡ሻே௡ୀଵ  , 𝑣 ൌ  
∑ 𝑆ሺ𝜆௡ሻ sin ሺ2𝜋𝑛 𝑁⁄ ሻே௡ୀଵ
∑ 𝑆ሺ𝜆௡ሻே௡ୀଵ  
where S(λ1), …, S(λN) is the SRS spectrum at individual voxels for N spectral points (λ1, …, λN). 
As 13 wavenumbers were sampled in multispectral SRS imaging, N = 13. The whole 4D dataset 
is projected onto a 2D Fourier space: each voxel in the real space (x,y,z) corresponds to a point in 
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the phasor space (u,v). Multiple regions that contained only one type of species (such as axon, 
vasculature, or nuclei) were cropped manually (as the procedure in Reference (9)) based on 
structural features in the unmixed protein and lipid images and then transformed to a reference 
phasor plot. According to the positions of individual species on the reference phasor plot, the 
phasor plot of the whole volumetric multispectral image was divided into several clusters 
representing these species. Each cluster on the phasor plot was projected to a binary volumetric 
image stack using custom-written Matlab scripts. Volume-rendered binary images were generated 
using Imaris and evaluated for the segmentation results. Several rounds of clustering, projection, 
and evaluation were conducted to achieve good segmentation. Volume fractions of individual 
species were calculated as the sum of all the voxels divided by the total number of voxels in the 
binary volumetric image stack. The total number of voxels in the dense tumor or the normal tissue 
was determined by delineating tumor margins using the raw image at 2940 cm-1 and dividing all 
the voxels into tumor or normal group accordingly. Single-cell spectra were generated by cropping 
regions of individual cells and plotting the signal intensity at different wavenumbers. 
 
Quantification of minimal distances 
Quantification of minimal distances was conducted using Volocity (PerkinElmer). For noise 
reduction, a median filter was applied to binary image stacks of tumor cells, vasculature, and 
axons. Individual tumor cells, blood vessels, and axons were identified using “Find object” with 
intensity thresholds and volume thresholds. Distances from the centroids of tumor cells to the 
edges of blood vessels/axons were quantified using “Measure distance”. The results of distances 
were exported and plotted as histograms of minimal distances. 
 
Quantification of metabolic activities in vasculature and clusters of newly synthesized lipids 
Quantification of metabolic activities in vasculature and clusters of newly synthesized lipids was 
conducted using Volocity (PerkinElmer) and ImageJ (8). First, tumor and normal tissues were 
segmented using “Find object” with intensity thresholds in the CDP channel. A mask of vasculature 
was generated using the Tubeness filter (ImageJ) in the CHP channel. Vasculature in tumor tissue 
was identified using “Intersect” between the mask of vasculature and the segmented tumor tissues. 
Vasculature in normal tissues was identified using “Intersect” between the mask of vasculature 
and the segmented normal tissues. CDP, CDL, CHP, and CHL intensities were measured for each 
identified blood vessels in tumor and normal tissues. Clusters of newly synthesized lipids were 
segmented using “Find object” with intensity thresholds and volume thresholds in the CDL 
channel. Clusters in tumor tissues were identified using “Intersect” with the segmented tumor 
tissues. Clusters in normal tissues were identified using “Intersect” with the segmented normal 
tissues. Volume and CDL intensities were measured for each identified clusters in tumor and 
normal tissues. 
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Fig. S1. Spontaneous Raman spectra. (A) Spontaneous Raman spectra of 8 M urea solution. (B) 
Spontaneous Raman spectra of cells treated with d-PA.  
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Fig. S2. 0.2% Triton X-100 alone cannot clear tissue. Photos and SRS images of 1 mm-thick brain slices 
in PBS and those treated with 0.2% Triton X-100 alone. Scale bars: 1mm for photos (Upper), 50 µm for 
SRS images (Lower). 
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Fig. S3. Preservation of tissue structures after tissue clearing. (A and B) SRS images of regions in the white 
matter (A) and the hippocampus (B). Top row, lipid channel; bottom row, protein channel. Left column, 
before clearing; middle column, after clearing; right column, merge. Scale bars, 50 µm. 
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Fig. S4. Treatment of 15% Triton X-100 disrupts lipid structures. (A) Raman spectra of mouse brain slices 
in PBS and those treated with 8 M urea and 15% Triton X-100 for 4 days and then restored with 8 M urea 
and 0.2% Triton X-100 for 4 days. (B) SRS images of the white matter, the cerebral cortex, and the 
hippocampus from the restored tissue. Left column, protein; right column, lipid. Scale bar, 50 µm. 
  
  15
 
Fig. S5. 3DISCO disrupts lipid structures. (A) Raman spectra of mouse brain slices in PBS and those treated 
with the 3DISCO method and then restored with PBS for 4 days. (B) SRS images of the white matter and 
the cerebral cortex from the restored tissue. Left column, protein; right column, lipid. Scale bar, 50 µm. 
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Fig. S6. 0.2% Triton X-100 removes lipids from multicellular tumor spheroids. SRS images of the 
multicellular tumor spheroid treated with 8 M urea and 0.2% Triton X-100. Left, protein; right, lipid. Scale 
bar, 50 µm. 
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Fig. S7. Optimal incubation time for tissue clearing for 1 mm brain tissues in 8 M urea and 0.2% triton X-
100. Photos of the brain slices after different days of tissue clearing treatment. Scale bar, 2 mm. 
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Fig. S8. Volumetric chemical imaging of various regions in mouse brains. (A) 3D reconstruction of the 
hippocampus and white matter. Arrows indicate vasculatures, arrowheads indicate axons, and stars indicate 
cell bodies. (B-D) 2D images at increasing depths of A. (E-G) 3D reconstruction of the white matter. Arrows 
indicate nerve tracts. (H) 3D reconstruction of the choroid plexus. Arrows indicate the choroid plexus and 
arrowheads indicate nerve tracts. (I) 3D reconstruction of the hippocampus. Arrows indicate vasculatures 
and arrowheads indicate axons. (J-L) orthogonal views of the hippocampus in I. J, xy view; K, yz view; L, 
xz view. (M) 3D reconstruction of the hippocampus. Arrows indicate vasculatures, arrowheads indicate 
axons, and stars indicate cell bodies. Scale bars, 50 µm. 
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Fig. S9. Reference phasor plot of mouse brain tissues. The right plot is a zoom-in view of the left plot. 
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Fig. S10. Single-plane images of segmentation by volumetric phasor analysis in different mouse brain 
regions. The color code is the same as that in Fig. 3 B-D: green, axon; blue, nucleus; magenta, vasculature; 
purple, water; cyan, other components. Scale bar: 50 µm. 
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Fig. S11. Volumetric chemical imaging of the glioblastoma in the brain. (A) 2D images of the tumor in the 
whole coronal slice at increasing imaging depths (same as Fig. 4A). (B) 2D images of the white-box region 
in A at increasing imaging depths.  (C) Zoom-in images of the white dash-line region in B. Imaging depths 
of A are labeled at the bottom left. Imaging depths of B and C are labeled at the top regions of B. Protein, 
magenta. Lipid, green. Scale bars: 1mm in A, 50 µm in B, 20 µm in C. 
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Fig. S12. Immunolabeling with a human-specific vimentin antibody confirms the tumor margin. Correlative 
images of immunofluorescence and SRS in the regions of (A) normal tissue, (B) tumor margin, and (C) 
tumor. Scale bar: 20 µm.
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Fig. S13. Protein/lipid ratiometric mapping of glioblastoma in mouse brain. Ratiometric images of the 
tumor in the whole coronal slice at increasing imaging depths. 
  
  24
 
Fig. S14. Phasor plots of brain glioblastoma tissues. (A) Reference phasor plots of brain glioblastoma 
tissues. The right plot is a zoom-in view of the left plot. (B) Phasor plots of the brain glioblastoma tissues 
in Fig. 6A. 
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Fig. S15. Immunolabeling with a human-specific vimentin antibody confirms tumor margins and 
infiltrating tumor cells identified by volumetric phasor analysis. The arrow indicates an infiltrating tumor 
cell. Left, SRS image. Middle, tumor cell nuclei identified by volumetric phasor analysis. Right, 
immunofluorescence image of vimentin. Scale bar: 20 µm. 
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Fig. S16. Stimulated Raman histology (10) confirms tumor margins and infiltrating tumor cells identified 
by volumetric phasor analysis. The arrow indicates an infiltrating tumor cell. Left, SRS image. Middle, 
tumor cells identified by volumetric phasor analysis. Right, image of stimulated Raman histology. Scale 
bar: 50 µm. 
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Fig. S17. Correlative two-photon fluorescence and SRS imaging of brain glioblastoma. Volume-rendered 
images of vasculature (two-photon autofluorescence, blue), lipids (SRS, green), proteins (SRS, magenta), 
and the merge. Imaging depths are labeled at the left of the autofluorscence images. White dash lines 
delineate the boundaries between tumor and normal tissues. Scale bars: 50 µm.  
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Fig. S18. Correlative second-harmonic generation and SRS imaging of subcutaneous glioblastoma. 
Volume-rendered images of collagen (second-harmonic generation, cyan), lipids (SRS, green), proteins 
(SRS, magenta), and the merge. Imaging depths are labeled at the lower right of the second-harmonic 
generation images. Scale bars: 50 µm.  
 
 
 
